Inhibin A-A Promising Predictive Parameter for Determination of Final Oocyte Maturation in Ovarian Stimulation for IVF/ICSI.
Inhibin A
Inhibin B
estradiol
oocyte maturity
ovarian stimulation
Journal
Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782
Informations de publication
Date de publication:
2020
2020
Historique:
received:
25
02
2020
accepted:
22
04
2020
entrez:
6
6
2020
pubmed:
6
6
2020
medline:
29
5
2021
Statut:
epublish
Résumé
The number of mature oocytes is a key factor in the success of Assisted Reproductive Techniques (ART). Exogenous gonadotropins are administered during ovarian stimulation in order to maximize the number of oocytes available for fertilization. During stimulation, monitoring is mandatory to evaluate individual response, to avoid treatment complications and assist in the determination of the optimal day for final oocyte maturation and oocyte retrieval. Routine monitoring during stimulation includes transvaginal ultrasound examinations and measurement of serum estradiol (E2). Due to multifollicular growth of follicles of varying size, serum E2 levels are commonly supraphysiological and often variable, rendering E2-measurement during ovarian stimulation unreliable as a determinant of oocyte maturity. In contrast to serum E2, serum Inhibin A levels increase once a minimum follicle size of 12-15 mm is achieved. Due to this fact, serum Inhibin A levels could present in combination with ultrasound monitoring a more reliable parameter to determine the optimal follicle size for final oocyte maturation, as only follicles with a size of 12 mm and beyond will contribute to the serum Inhibin A level. This prospective observational, cross-sectional study demonstrates, that on the day of final oocyte maturation serum Inhibin A is strongly correlated to the number of follicles ≥15 mm (0.72) and to the number of retrieved and mature oocytes (ρ 0.82/0.77, respectively), whereas serum E2 is moderately correlated to the parameters mentioned above (ρ 0.64/0.69/0.69, respectively). With an area under the curve (AUC) of 0.91 for Inhibin A, compared to an AUC of 0.84 for E2, Inhibin A can be regarded as a better predictor for the optimal timing of trigger medication with a threshold number of ≥10 mature oocytes. It can be concluded from this data that serum Inhibin A in combination with transvaginal ultrasound monitoring may be a more powerful tool in the decision making process on trigger timing as compared to E2.
Identifiants
pubmed: 32499758
doi: 10.3389/fendo.2020.00307
pmc: PMC7243678
doi:
Substances chimiques
Biomarkers
0
inhibin A
0
Inhibins
57285-09-3
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
307Informations de copyright
Copyright © 2020 Lawrenz, Depret Bixio, Coughlan, Andersen, Melado, Kalra, Savjani, Fatemi and Kumar.
Références
Hum Reprod Update. 2014 Jan-Feb;20(1):124-40
pubmed: 24077980
Semin Reprod Med. 2004 Aug;22(3):187-93
pubmed: 15319821
Mol Cell Endocrinol. 2004 Oct 15;225(1-2):37-44
pubmed: 15451566
Reprod Biol Endocrinol. 2014 Nov 24;12:107
pubmed: 25420733
Fertil Steril. 2018 Sep;110(4):661-670.e1
pubmed: 30196963
Shanghai Arch Psychiatry. 2018 Jun 25;30(3):207-212
pubmed: 30858674
Curr Opin Obstet Gynecol. 2012 Jun;24(3):151-7
pubmed: 22487725
Cochrane Database Syst Rev. 2008 Apr 16;(2):CD005289
pubmed: 18425917
Front Endocrinol (Lausanne). 2018 Jan 12;8:376
pubmed: 29375481
Anesth Analg. 2018 May;126(5):1763-1768
pubmed: 29481436
Front Endocrinol (Lausanne). 2018 Apr 25;9:193
pubmed: 29743877
Hum Reprod. 1999 Feb;14(2):409-15
pubmed: 10099988
J Clin Endocrinol Metab. 2000 Feb;85(2):607-13
pubmed: 10690863
Hum Reprod. 2000 Jul;15(7):1499-504
pubmed: 10875856
Hum Reprod. 1994 Sep;9(9):1631-3
pubmed: 7836512
Biol Reprod. 1989 Jan;40(1):33-47
pubmed: 2493821
Mol Hum Reprod. 2017 Jan;23(1):16-24
pubmed: 27756855
Fertil Steril. 2003 Jul;80(1):80-5
pubmed: 12849805
Hum Reprod. 2003 Apr;18(4):665-7
pubmed: 12660254
Cochrane Database Syst Rev. 2014 Aug 24;(8):CD005289
pubmed: 25150465
Hum Reprod. 2003 Jun;18(6):1140-1
pubmed: 12773437
J Clin Endocrinol Metab. 1993 Nov;77(5):1402-10
pubmed: 8077341
Endocr Rev. 2006 Apr;27(2):170-207
pubmed: 16434510
Gynecol Endocrinol. 1990 Dec;4(4):261-9
pubmed: 2127985
Gynecol Endocrinol. 2014 Sep;30(9):649-52
pubmed: 24811095
Fertil Steril. 2015 Mar;103(3):e9-e17
pubmed: 25585505
Fertil Steril. 2006 Jan;85(1):112-20
pubmed: 16412740
Front Endocrinol (Lausanne). 2019 May 08;10:281
pubmed: 31139145
Ultrasound Obstet Gynecol. 2018 Jan;51(1):118-125
pubmed: 29134715
J Clin Endocrinol Metab. 1993 Nov;77(5):1227-34
pubmed: 7521343
Hum Reprod. 2019 Jan 01;34(1):171-180
pubmed: 30541039
Fertil Steril. 2017 Aug;108(2):262-268
pubmed: 28601410
Hum Reprod. 2016 Sep;31(9):1997-2004
pubmed: 27343272
Hum Reprod. 2011 Jul;26(7):1768-74
pubmed: 21558332
Fertil Steril. 1997 May;67(5):889-99
pubmed: 9130895
J Assist Reprod Genet. 2017 Oct;34(10):1341-1351
pubmed: 28710674
Eur J Endocrinol. 2005 Mar;152(3):395-401
pubmed: 15757856
Fertil Steril. 2018 Apr;109(4):577-582
pubmed: 29653703
Fertil Steril. 2005 Feb;83(2):341-8
pubmed: 15705372
Obstet Gynecol. 2015 Jan;125(1):268-73
pubmed: 25560143
Fertil Steril. 1996 Apr;65(4):687-701
pubmed: 8654622